-
Early research indicates that beneficial bacteria found in the healthy vagina aids in reducing the amount of vaginal HIV among HIV-infected women and may make it more difficult for the virus to spread.
-
Check the next four files of your teenage female patients: chances are one of these young women has a sexually transmitted disease (STD), according to study results just released by the Centers for Disease Control and Prevention (CDC).
-
Be sure to pencil in dates for two upcoming women's health conferences sponsored by the Association of Reproductive Health Professionals, Planned Parenthood Federation, the Society of Family Planning, and the National Association of Nurse Practitioners in Women's Health (NPWH).
-
Bad news: Results of the first large-scale effectiveness trial for a microbicide indicate that while the candidate, Carraguard, is safe, it was not shown to be effective in preventing male-to-female transmission of HIV.
-
An experimental anti-HIV tenofovir gel is safe for women to use on a daily basis, according to research conducted by the scientists at the University of Pittsburgh (PA) School of Medicine and the University of Alabama at Birmingham (UAB).
-
-
Several strides have been made when it comes to cervical cancer prevention. Research has identified high-risk human papillomaviruses (HPVs) as causal agents, a test has been developed to detect HPV infection (Digene HPV Test, Digene Corp.; Gaithersburg, MD), and a vaccine (Gardasil, Merck & Co.; Whitehouse Station, NJ) is now marketed to prevent infection of the most common types of HPV.
-
In 1998, the United States was on the verge of eliminating syphilis, one of the most prevalent sexually transmitted diseases (STDs). Today, the national syphilis rate has increased for the seventh consecutive year, according to preliminary data presented at the March 2008 National STD Prevention Conference.
-
Disruptive behaviors are a poor prognostic sign in patients with Alzheimer's disease.
-
Wyeth Pharmaceuticals has received approval to market desvenlafaxine for the treatment of depression. The drug is the major active metabolite of venlafaxine (Effexor ). Wyeth has formulated the drug in a once-daily extended-release tablet. It will be marketed under the trade name Pristiq.
